Follow-up care for new cases of polyarthritis in children and young adults
Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults. Optimization of Clinical Response, Remission, Quality of Life and Analysis of Prognostic Markers
This program will try standardized medical follow-up for children and young adults (≤50) with new-onset JIA, RA, psoriatic/seronegative/undifferentiated arthritis, SLE, or diffuse systemic sclerosis who are treatment-naïve or treated ≤3 months to see if more patients reach disease control or remission.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 2 Years to 50 Years |
| Sex | All |
| Sponsor | Université Catholique de Louvain Academic / other |
| Locations | 1 site (Brussels) |
| Trial ID | NCT07000916 on ClinicalTrials.gov |
What this trial studies
This observational program will enroll young patients (up to 50 years) newly diagnosed with juvenile idiopathic arthritis, rheumatoid/psoriatic/seronegative/undifferentiated arthritis, systemic lupus erythematosus, or diffuse systemic sclerosis who are treatment‑naïve or treated ≤3 months (except JIA). Participants will be organized into five disease cohorts and undergo standardized clinical monitoring with predefined response and remission criteria based on international definitions. The project seeks to progressively increase capture of new incident cases—targeting 25% initially with a 20% annual increase over 5–10 years—to harmonize care across the participating French‑speaking university centers. Primary outcomes include the proportion of patients achieving good disease control or clinical remission under the standardized follow‑up.
Who should consider this trial
Good fit: Children and young adults aged ≤50 with a new diagnosis of JIA, RA, psoriatic/seronegative/undifferentiated arthritis, SLE, or diffuse systemic sclerosis who are treatment‑naïve or have received basic therapy for ≤3 months (except JIA) are ideal candidates.
Not a fit: Patients treated for more than 3 months, older than 50, or with established long-standing disease are unlikely to benefit from the early standardized follow-up targeted here.
Why it matters
Potential benefit: If successful, this approach could increase the number of young patients who achieve good disease control or clinical remission through earlier, standardized follow-up and care.
How similar studies have performed: Early-treatment and standardized monitoring approaches have improved remission rates in RA and JIA in prior work, though combining multiple pediatric and young adult rheumatic diseases in a single standardized program is less commonly studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of juvenile idiopathic arthritis, rheumatoid arthritis and seronegative / psoriatic / undifferentiated arthritis, systemic lupus erythematosus or diffuse systemic sclerosis (ACR criteria). * Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA. Exclusion Criteria: * Treated for \> 3 months * \> 50 years old
Where this trial is running
Brussels
- UCLouvain — Brussels, Belgium (Recruiting)
Study contacts
- Study coordinator: Patrick Durez
- Email: patrick.durez@uclouvain.be
- Phone: +32 02 764 53 89
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.